Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) EBIT Margin: 2014-2025

Historic EBIT Margin for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to 5.15%.

  • Ascendis Pharma A's EBIT Margin rose 17243.00% to 5.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -21.69%, marking a year-over-year increase of 7490.00%. This contributed to the annual value of -76.66% for FY2024, which is 9414.00% up from last year.
  • Ascendis Pharma A's EBIT Margin amounted to 5.15% in Q3 2025, which was up 115.36% from -33.50% recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's EBIT Margin peaked at 5.15% during Q3 2025, and registered a low of -16,709.12% during Q1 2021.
  • In the last 3 years, Ascendis Pharma A's EBIT Margin had a median value of -103.23% in 2025 and averaged -159.22%.
  • Examining YoY changes over the last 5 years, Ascendis Pharma A's EBIT Margin showed a top increase of 1,557,822bps in 2021 and a maximum decrease of 1,341,900bps in 2021.
  • Over the past 5 years, Ascendis Pharma A's EBIT Margin (Quarterly) stood at -2,298.98% in 2021, then spiked by 165,523bps to -643.75% in 2022, then surged by 61,717bps to -26.59% in 2023, then soared by 2,681bps to 0.22% in 2024, then surged by 17,243bps to 5.15% in 2025.
  • Its EBIT Margin was 5.15% in Q3 2025, compared to -33.50% in Q2 2025 and -103.23% in Q1 2025.